TargetMol

Benzetimide hydrochloride

Product Code:
 
TAR-T7561
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T7561-10mg10mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7561-1mL1 mL * 10 mM (in DMSO)£114.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7561-25mg25mg£131.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7561-50mg50mg£152.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7561-100mg100mg£176.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Benzetimide hydrochloride is an antagonist of muscarinic acetylcholine receptor.treatment neuroleptic-induced parkinsonism.
CAS:
5633-14-7
Formula:
C23H27ClN2O2
Molecular Weight:
398.93
Pathway:
Neuroscience
Purity:
0.98
SMILES:
Cl.O=C1CCC(C2CCN(Cc3ccccc3)CC2)(C(=O)N1)c1ccccc1
Target:
AChR

References

Klaassen A B M , Kuijpers W , Scheres H M E , et al. Cholinergic Receptors in the Upper Respiratory System of the Rat[J]. Archives of Otolaryngology - Head and Neck Surgery, 1986, 112(4):428-431. Kovacs I , Yamamura H I , Waite S L , et al. Pharmacological comparison of the cloned rat and human M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line[J]. Journal of Pharmacology and Experimental Therapeutics, 1998, 284(2):500-507.